Blog
RSS FeedPosted by Michael Wonder on 17 Dec 2024
ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 14 May 2021
Making cancer treatments affordable today won’t hurt tomorrow’s innovation
12 May 2021 - Congress is about to debate legislation—the Lower Drug Costs Now Act (H.R.3)—that would give Medicare the ...
Posted by Michael Wonder on 05 Apr 2021
ICER publishes evidence report on therapies for multiple myeloma
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
Posted by Michael Wonder on 12 Feb 2021
ICER releases draft evidence report on therapies for multiple myeloma
11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on new therapies for bladder cancer
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
Posted by Michael Wonder on 31 Aug 2020
ICER to assess CAR-T cell therapies for multiple myeloma
31 August 2020 - Report will be subject of Midwest CEPAC meeting in April 2021; open input now being accepted until ...
Posted by Michael Wonder on 01 May 2020
The global imperative to make cancer medications affordable
1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...
Posted by Michael Wonder on 15 Oct 2019
Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...
Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...
Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...
Posted by Michael Wonder on 09 Aug 2017
Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment
9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA. ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 07 Jun 2017
Converging on the value of value frameworks
6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...
Posted by Michael Wonder on 29 Sep 2016
ICER releases evidence report on treatments for non-small cell lung cancer
29 September 2016 - The Institute for Clinical and Economic Review has released an evidence report assessing the comparative clinical effectiveness ...